Your session is about to expire
← Back to Search
Bi-specific Antibodies for Melanoma
Study Summary
This trial will assess a new bi-specific antibody to treat advanced melanoma, to see if it is safe, tolerable, and potentially more effective than existing treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am on certain medications that I cannot or do not want to stop before starting the study drugs.I am still experiencing side effects from previous cancer treatments.I have had up to 4 treatments for my cancer after it spread.I have previously received BRAF targeted therapies.I am on long-term steroid treatment above normal replacement levels.I had a stem cell transplant from a donor within the last 5 years.I have no uncontrolled health conditions besides my cancer.I have had serious lung inflammation before or have it now.I am HIV-positive and have had Kaposi's sarcoma or Multicentric Castleman's Disease.My organs are functioning well, as tested within the last 14 days.I have been diagnosed with an immune system disorder.I have an autoimmune disease treated with medication in the last 2 years.I am still recovering from major surgery or have a significant infection after surgery.I have brain metastases needing steroids.I may have brain involvement, but it's allowed for the treatment phase I'm entering.My HIV is well-controlled with medication.I am eligible for the next phase of treatment based on my brain disease status.My cancer has worsened despite treatment with specific immune therapies.My cancer can be measured by scans.I am 18 years old or older.I am fully active or restricted in physically strenuous activity but can do light work.I have undergone more than 4 treatments for cancer that has spread.I have had severe immune system reactions in the past.I have Hepatitis B or C and am not stable on treatment.I have an infection that is not under control and needs treatment.My melanoma is confirmed advanced/metastatic by a pathology report.I've had immunotherapy without severe side effects.I have not received a live vaccine in the last 30 days.
- Group 1: Phase 2: Dose Expansion (Cohort A)
- Group 2: Phase 1b: Dose Escalation (Cohort 3)
- Group 3: Phase 2: Dose Expansion (Cohort B)
- Group 4: Phase 1b: Dose Escalation (Cohort 1)
- Group 5: Phase 1b: Dose Escalation (Cohort 2)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any opportunities for participation in this investigation currently available?
"Evidenced by the clinicaltrials.gov page, this medical trial has ceased recruiting patients; its initial posting on April 1st 2023 was followed up with an edit on January 13th 2023. Despite not being presently enlisting volunteers, there are 752 other trials that require involvement from test subjects."
What insights is this research endeavor attempting to uncover?
"Over the course of two years, researchers leading this clinical trial will evaluate Treatment-Emergent Immune-Related Adverse Events (Part 1) as their primary endpoint. Secondary endpoints include Area under the Curve (AUC), Mean Minimum Concentration (Cmin), and Mean Maximum Concentration (Cmax). All three metrics will be assessed by monitoring serum levels of XmAb23104 and XmAb22841 from day one through follow up visits until completion."
Share this study with friends
Copy Link
Messenger